Eton Pharmaceuticals (ETON) EBIT (2018 - 2026)

Eton Pharmaceuticals has disclosed EBIT across 9 years of filings, most recently posting $12.8 million for Q2 2026.

• In Q2 2026, EBIT rose 967.39% year-over-year to $12.8 million; the TTM figure through Jun 2026 stood at $12.4 million (up 1639.03% YoY), while the FY2025 annual figure was -$844000.0, up 67.5% from the prior year.
• EBIT came in at $12.8 million for Q2 2026 at Eton Pharmaceuticals, up from $2.5 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $12.8 million in Q2 2026 to a low of -$5.1 million in Q1 2022.
• Average EBIT over 5 years is -$5823.5, with a median of -$800000.0 recorded in 2024.
• Year-over-year, EBIT plunged 367.78% in 2025 and jumped 967.39% in 2026.
• Over 5 years, EBIT stood at $1.1 million in 2022, then slumped by 287.66% to -$2.0 million in 2023, then jumped by 131.56% to $629000.0 in 2024, then soared by 291.73% to $2.5 million in 2025, then soared by 419.24% to $12.8 million in 2026.
• Per Business Quant data, the three most recent EBIT figures were $12.8 million in Q2 2026, $2.5 million in Q4 2025, and -$1.4 million in Q3 2025.